by Elena Iemma | Dec 9, 2024 | News
EpiVax Drives Immunogenicity Innovation in 2024: Year in Review PROVIDENCE, R.I., Dec. 6, 2024 — EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by...
by Elena Iemma | Dec 6, 2024 | News
PROVIDENCE, R.I., Dec. 6, 2024 — EpiVax, a leader in biotechnology known for its advanced immunoinformatics tools, proudly announces its continued support for two nonprofits, Clínica Esperanza/Hope Clinic and GAIA Vaccine Foundation....
by Elena Iemma | Oct 24, 2024 | News
PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ — EpiVax, Inc. and CUBRC, Inc. announce today that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug...
by Elena Iemma | Oct 18, 2024 | Events, News
The 10th annual Amsterdam Immunogenicity and Tolerance Seminar was a fantastic success, bringing together a passionate group of immunology and vaccinology experts to explore new frontiers in the field. The morning sessions focused on protein therapeutics, with...
by Elena Iemma | Mar 29, 2024 | News
PROVIDENCE, RI, April 1, 2024 /PRNewswire/ — Read the publication. In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational tools for predicting and managing immunogenicity risk –...
by Elena Iemma | Feb 23, 2024 | News
If you missed the posters that we presented at AAPS NBC 2024, don’t worry! Click each poster below to enlarge it or download. Have questions or interested in discussing these studies more? Send us a message here. An “I” (Immunogenicity Risk...
